–A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative
Open Access
- 11 November 2025
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-15
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies, and the treatment options are limited. Growing evidence shows that long non-coding RNAs (LncRNAs) encode peptides, suggesting that lncRNAs-derived peptides may play a role in HCC progression and explore their potential as therapeutic targets. We used RNA-sequencing and bioinformatics analysis to identify a 107-amino acid peptide, SMIM45-107aa, encoded by LINC00634. The expression levels and prognostic significance of SMIM45-107aa in HCC tissues were assessed by immunohistochemistry (IHC) and Kaplan-Meier. Wound-healing and cell colony formation evaluate the effects of SMIM45-107aa on cell migration and proliferation. A mouse xenograft model was used to examine the tumor formation. Interactions between SMIM45-107aa and MTDH were explored and the effects on MTDH ubiquitination were investigated by immunoprecipitation. Proteomic analysis and Western blotting confirmed the mechanism of SMIM45-107aa effected HCC. Additionally, a short peptide, peptide 5 derived from SMIM45-107aa was analyzed by cell migration in SK-Hep1 cells and by zebrafish model. SMIM45-107aa was highly expressed in HCC tissues and associated with poor prognosis. It promoted cell migration and proliferation in vitro and tumor formation in vivo. SMIM45-107aa interacted with MTDH, inhibiting its ubiquitination and stabilizing the protein. Proteomic and Western blot analysis revealed that SMIM45-107aa upregulated MGST1 and phosphorylated AKT (pAKT). Importantly, peptide 5 inhibited SMIM45-107aa-induced cell migration and demonstrated anticancer activity in zebrafish models. We identified SMIM45-107aa, a novel peptide encoded by LINC00634, which promoted HCC progression via the MGST1-pAKT-MTDH axis. The derived peptide 5 exhibited anticancer activity, suggesting a potential therapeutic strategy for HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81972574)
- Project of Leading Talents of Tongren Hospital (TRKYRC-lj202205)
- Research Fund of Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine (2023DHYGJC-ZDB01)
This publication has 40 references indexed in Scilit:
- USP7 promotes cervical cancer progression by stabilizing MTDH expression through deubiquitinationJournal of Cancer Research and Clinical Oncology, 2024
- USP22 aggravated diabetic renal tubulointerstitial fibrosis progression through deubiquitinating and stabilizing Snail1European Journal of Pharmacology, 2023
- LINC00998‐encoded micropeptide SMIM30 promotes the G1/S transition of cell cycle by regulating cytosolic calcium levelMolecular Oncology, 2022
- A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer ActivityCell Chemical Biology, 2018
- Peptidomimetic therapeutics: scientific approaches and opportunitiesDrug Discovery Today, 2017
- Co-delivery of chemotherapeutics and proteins for synergistic therapyAdvanced Drug Delivery Reviews, 2016
- Structure‐Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding EpitopesAngewandte Chemie International Edition, 2015
- Protein–protein interactions and genetic diseases: The interactomeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the RealityChemistry & Biology, 2014
- AEG-1/MTDH/LYRIC in Liver Cancer2013